Market Trends of Global Peptide Synthesis Industry
This section covers the major market trends shaping the Peptide Synthesis Market according to our research experts:
Pharmaceutical and Biotechnology Companies are Expected to Hold a Significant Market Share Over the Forecast Period
The research and developments of peptide therapies are increasing, as they are cost-effective, efficient, and have lower toxicity. The major factor driving the market for peptide synthesis in pharmaceutical and biotechnology companies is rapid technological advancements in peptide synthesizers and a strong peptide therapeutics pipeline. For instance, the article published in Science Direct in 2022 under the title 'Advances in oral peptide drug nanoparticles for diabetes mellitus treatment' stated that a promising approach to treating diabetes mellitus is through oral administration of peptide medications. In comparison to parenteral administration methods, oral administration of peptide medicines is found to be a potential approach for the treatment of diabetes mellitus due to its ease and high patient compliance.
Product launches, mergers, and acquisitions presence of competitors are boosting the market growth. For instance, in January 2022, Novo Nordisk India launched the world's first 'Peptide In A Pill' for diabetes management. The peptide named, Semaglutide, a GLP-1 receptor analog (GLP-1 RA), is one of the drug classes for the management of type 2 diabetes. All these developments are expected to propel the growth of the pharmaceutical and biotechnology end-user segment in the peptide synthesis market.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to dominate the overall peptide synthesis market throughout the forecast period. The dominance is due to the growing prevalence of obesity with a rise in sedentary deskbound lifestyles, and lack of proper diet and physical activity resulting in various chronic diseases like diabetes in the United States necessitating efficient treatment. For instance, according to the International Diabetic Federation 2021 report, an estimated 51 million adults aged 20-29 years were living with diabetes in the North America Caribbean (NAC) region in 2021, representing a regional prevalence of 14.6%. This region has the second highest number of children and adolescents with type 1 diabetes (193,000). The high prevalence of diabetes is expected to continue resulting in higher demand for peptide therapeutics driving the market in the studied region.
Furthermore, the increased availability of advanced healthcare infrastructure and huge investments by the key players in this region to develop new peptide synthesis technologies are also likely to fuel the market growth. For instance, in 2020 the United States Food and Drug Administration (US FDA) approved Imcivree (setmelanotide), a pro-opiomelanocortin-derived peptide for chronic weight management (weight loss and weight maintenance for at least one year) in patients for six years and older with obesity due to rare genetic conditions. Accelerated drug approval initiative by the US FDA is also likely to fuel the market growth in this region across the forecast period, contributing to its outstanding market share in the global peptide synthesis market.
